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Polyglutamine (polyQ) expansion mutation causes conformational, neurodegenerative diseases, such as Alzheimer’s and
Parkinson’s diseases. These diseases are characterized by the aggregation of misfolded proteins, such as amyloid fibrils, which
are toxic to cells. Amyloid fibrils are formed by a nucleated growth polymerization reaction. Unexpectedly, the critical nucleus
of polyQ aggregation was found to be a monomer, suggesting that the rate-limiting nucleation process of polyQ aggregation
involves the folding of mutated protein monomers. The monoclonal antibody 1C2 selectively recognizes expanded pathogenic
and aggregate-prone glutamine repeats in polyQ diseases, including Huntington’s disease (HD), as well as binding to
polyleucine. We have therefore assayed the in vitro and in vivo aggregation kinetics of these monomeric proteins. We found
that the repeat-length-dependent differences in aggregation lag times of variable lengths of polyQ and polyleucine tracts
were consistently related to the integration of the length-dependent intensity of anti-1C2 signal on soluble monomers of these
proteins. Surprisingly, the correlation between the aggregation lag times of polyQ tracts and the intensity of anti-1C2 signal on
soluble monomers of huntingtin precisely reflected the repeat-length dependent age-of-onset of HD patients. These data
suggest that the alterations in protein surface structure due to polyQ expansion mutation in soluble monomers of the mutated
proteins act as an amyloid-precursor epitope. This, in turn, leads to nucleation, a key process in protein aggregation, thereby
determining HD onset. These findings provide new insight into the gain-of-function mechanisms of polyQ diseases, in which
polyQ expansion leads to nucleation rather than having toxic effects on the cells.
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to Nucleation of Protein Aggregate: Determinant of Huntington’s Disease Onset. PLoS ONE 2(7): e635. doi:10.1371/journal.pone.0000635
INTRODUCTION
To date, nine polyglutamine (polyQ) diseases have been identified:
Huntington’s disease (HD), spinal and bulbar muscular atrophy,
spinocerebellar ataxia (types 1, 2, 3, 6, 7, and 12) and
dentatorubral-pallidoluysian atrophy, each of which results from
an abnormally increased number of residues in a polyQ tract of
the corresponding gene product [1]. The monoclonal antibody
(mAb) 1C2 has been found to selectively discriminate among
critical polyQ lengths [2], [3]. Since the increased length of polyQ
proteins has been associated with earlier onset and more severe
manifestation of the disease state, expansion of the polyQ tract is
thought to be the key causal element of the disease process [4].
PolyQ diseases have been found to belong to a wide range of
neurodegenerative diseases associated with protein misfolding and
aggregation, including Alzheimer’s, prion and Parkinson’s diseases
[5], [6]. In many of these conditions, protein deposition involves
the formation of amyloid fibrils, and polyQ aggregates show many
of the attributes of amyloid [7], [8]. Although the role of
aggregation and fibril formation in these disorders has not yet been
established, protein misfolding and aggregation are thought to be
the central issues for understanding the molecular mechanisms of
polyQ pathogenesis [4]. Amyloid fibril growth is considered to be
controlled by nucleated growth polymerization, a two-stage
process consisting of the energetically unfavorable formation of
a nucleus, followed by efficient elongation of the nucleus via
sequential additions of monomer [9], [10].
Recent analysis of the in vitro aggregation kinetics of a series of
polyQ peptides showed that polyQ aggregation was also due to
a nucleated growth polymerization reaction [11]. Moreover, the
repeat-length-dependent nucleation process of polyQ aggregation
was found to reflect the length related age-of-onset of HD. The
molecular bases of the relationship between repeat length and age-
of-onset and between polyQ expansion and protein aggregation,
however, are still unclear. Since the ability of the mAb 1C2 to
detect huntingtin also depends on the length of polyQ tracts, we
tested whether the nucleation process is related to the pathological
epitope detected by 1C2. Based on our findings, we have
hypothesized an amyloid-based polyQ pathogenic pathway that
can explain most of the features characteristic of polyQ diseases.
These include protein aggregate, threshold polyQ length, delayed
disease-onset, repeat-length related age-of-onset and selective loss
of neurons [1], [4], [12].
RESULTS
Aggregation lag times and anti-1C2 signal intensity
of polyQ expansions
The relative inverted values of the aggregation lag times of polyQ
peptides (Q28, Q36 and Q47) [11] were determined (Figure 1A).
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huntingtin containing variable lengths of polyQ tracts [2] was
adjusted relative to the intensity of anti-huntingtin mAb.
Surprisingly, both independent measurements of the inverted
values of the repeat-length-dependent differences in aggregation
lag times of polyQ tracts and the length-dependent intensity
differences of the anti-1C2 signal on polyQ tracts were identical
(Figure 1A). Furthermore, the relationship between aggregation
lag times and the intensity of the anti-1C2 signal was represented
by the function, y=ax
21 (a is the relative value), with each of the
rectangles having a constant area (Figure 1B), suggesting that the
length-dependent differences in aggregation lag times of polyQ
tracts are related to the integration of the length-dependent
intensity of the anti-1C2 signal on soluble polyQ monomers. In
agreement with this observation and in contrast to conventional
models of nucleated growth polymerization, the number of
monomeric units comprising the critical nucleus of polyQ
aggregation was equal to 1 [11], suggesting that the rate-limiting
step in the nucleation process of polyQ aggregation involves
folding within the monomer.
Aggregation lag times and anti-1C2 signal intensity
of polyL expansions
Polyleucine (polyL) tracts can be detected by 1C2, as well as
displaying a higher propensity for aggregation and toxicity in cells
compared to polyQ tracts [13]. To confirm the relationship
between the nucleation process of protein aggregation and the
pathological epitope detected by 1C2, we made constructs in
which variable lengths of polyL were fused to the N terminus of
green fluorescent protein (GFP) (Figure 2A). COS7 cells expressing
a series of polyL-GFP fusion proteins (L13, L24 and L32) and GFP
alone were serially observed for 120 h, and the numbers of
transfected cells with and without visible aggregate formation were
counted. When we assessed the time course of aggregate formation
in COS7 cells transfected with pQBI25-L32 or vector alone, we
found that, in contrast to cells transfected with vector alone
(pQBI25, 24 h), cells transfected with pQBI25-L32 show aggre-
gates of fusion protein in their nuclei (L32, 24 h) (Figure 2B). The
fraction of cells containing aggregates decreased 48 h after
transfection with pQBI25-L32 and 72 h after transfection with
pQBI25-L24 (Figure 2C), probably due to cell death caused by
aggregate formation. To clarify the effect of cell death due to
polyL expansion on aggregate formation, we serially monitored
dead cells by propidium iodide (PI) staining for 96 h after
transfection with pQBI25, pQBI25-L13, -L24 or -L32 (Figure 3A).
In contrast with cells transfected with pQBI25, a small percent of
GFP-positive cells died 36 h after transfection with pQBI25-L32
and 72 h after transfection with pQBI25-L24 (Figure 3B). The
percentage of dead cells in cultures transfected with pQBI25 or
pQBI25-L13 remained constant over 96 h after transfection.
Cells transfected with each construct, as well as mock
transfected cells, were serially collected after transfection and
analyzed by Western blotting using anti-GFP polyclonal antibody
(Figure 4A). To exclude the effect of dead cells due to polyL
expansion, cells transfected with pQBI25-L32 and pQBI25-L24
were monitored for only 24 and 48 h, respectively (Figure 3).
Equal amounts of protein lysates obtained from cells 24 h after
transfection were analyzed using 1C2 and anti-GFP antibody
(Figure 4B), with the intensity of each signal adjusted to that of the
sum of the constant squares as in Figure 2C. The time courses of
the intensity of the anti-GFP signal (Figure 4C) and anti-1C2
signal (Figure 4D) were then plotted, with the integration of
intensity of the anti-1C2 signal at each time point calculated by
Simpson’s formula. Remarkably, the integration of the repeat-
length-dependent intensity of the anti-1C2 signal (Figure 4E) was
consistent with the time course of formation of the length-
dependent aggregates (Figure 2C, p,0.05). These results suggest
that the repeat-length-dependent differences in aggregation lag
times of polyL-GFP fusion proteins are related to the integration of
the length-dependent intensity of the anti-1C2 signal on soluble
monomers of polyL-GFP fusion proteins.
Critical determinant of the repeat-length dependent
age-of-onset of HD
While the ability of 1C2 to detect the pathological epitope is
associated with the nucleation process of protein aggregates, it is
unclear whether this association reflects the process of polyQ
pathogenesis. We therefore assessed the relationship between the
function obtained from the results of Figure 1A and the repeat-
length dependent age-of-onset of HD patients. Results from a large
cohort, consisting of 661 affected and 205 asymptomatic at-risk
persons with polyQ expansion, showed that median age of HD
onset was related to CAG (glutamine) size [14] (Figure 5A).
Surprisingly, the inverted values of the quadratic function from the
Figure 1. Aggregation lag times and anti-1C2 signal intensity of
polyQ expansions. (A). Inverted values of the repeat-length-dependent
differences in aggregation lag times of a series of polyQ peptide
encoding repeats length of 28, 36 and 47 (Q28, Q36 and Q47) by Chen
et al. [11] (closed rectangles) and length-dependent intensity differ-
ences of anti-1C2 signals on soluble monomers of huntingtin encoding
repeats length of 27, 33 and 39 (Q27, Q33 and Q39) by Trottier et al. [2]
(closed triangles). The Spearman’s correlation coefficient was 1.00, with
the relationship represented by the function,
y=0.72(x225)
222.75(x225)+7.1. (B). Relationship between aggregation
lag times of polyQ tracts and intensity of anti-1C2 signal on soluble
monomers of huntingtin from the results of Figure 1A (y=ax
21,ai s
relative value). Each of the rectangles shows a constant area (=a).
doi:10.1371/journal.pone.0000635.g001
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the intensity of anti-1C2 signal on soluble monomers of huntingtin
perfectly reflected the repeat-length dependent age-of-onset of HD
(Figure 5A, Spearman’s correlation coefficient=1.00, p,0.001).
Despite the complexity of the cellular environment, including
degradation and transport processes capable of partitioning
proteins into different molecular forms and compartments, and
the presence of chaperones that modulate polyQ aggregation and
cellular toxicity [15], [16], our results strongly suggest that the
pathological epitope detected by 1C2 and its link to nucleation are
critical in determining HD onset. These findings also demonstrat-
ed that an additional factor, dependent on the repeat-length of
polyQ expansions or associated with aging brain, participates in
determining HD onset (Figure 5B). It is of interest that the
expression of huntingtin associated protein-1, a strong candidate
for involvement in HD pathology [17], [18], decreases in the aging
brain at the main pathological sites of HD, including the caudate
putamen, globus pallidus and neocortex [19].
DISCUSSION
Since the discovery of the androgen receptor gene mutation in the
polyQ diseases spinal and bulbar muscular atrophy [20], the
increased knowledge of various polyQ diseases has shown that the
unifying pathogenic mechanism of these diseases and of their
characteristic features arises from the expansion of polyQ itself [1],
[4], [12], [21]. To date, however, there has been no hypothetical
mechanism that can explain all of the features of these diseases. In
particular, an initial process directly linked to the pathogenic
mechanisms has not yet been discovered. The results presented
here show that the repeat-length-dependent differences in
aggregation lag times of variable lengths of polyQ and polyL
tracts are strictly linked to the length-dependent epitope detected
by the mAb 1C2, which selectively discriminates among the
pathological lengths of glutamine repeats in polyQ diseases [2],
[3]. Strikingly, the correlation between the inverted values of
aggregation lag times of polyQ tracts and the intensity of anti-1C2
signals on soluble monomers of huntingtin precisely reflects the
repeat-length dependent age-of-onset of HD patients. Consistent
with our findings, the rate-limiting nucleation process of polyQ
aggregation is thought to involve folding within mutant monomers
[11]. These data suggest that the protein surface structure detected
by 1C2 in soluble mutant monomers acts as an amyloid-precursor
epitope, leading to nucleation, a key process of protein
aggregation, and thereby determining HD onset. Moreover, 1C2
has been shown to inhibit the in vitro aggregation of the protein
implicated in HD [22].
Our results indicate that the gain-of-function of polyQ
pathogenesis involves two steps. A gain-of-toxic-function mecha-
nism for polyQ expansion mutation has been suggested by results
from cell transfection and transgenic and knock-out animal
experiments [12], [23]. Our findings suggest, however, that the
genetic gain-of-function conferred by polyQ expansion is a gain of
amyloid-precursor structure rather than a toxic effect on the cells.
This scenario may explain the puzzling relationship between
protein aggregation and cell toxicity, in that aggregate formation
does not necessarily result in cell death. For example, aggregates
have been detected in the dentate nucleus of the HD cerebellum,
Figure 2. Time course of aggregate formation by cells transfected with constructs expressing variable lengths of polyL-GFP fusion proteins. (A).
Agarose gel electrophoresis of PCR products amplified by a set of primers covering the inserted fragments of the constructs (Lane M, pBR322
digested with MspI as size marker; lane 1, pQBI25; lane 2, pQBI25-L13; lane 3, pQBI25-L24; lane 4, pQBI25-L32), and yielding PCR of sizes 153 bp,
228 bp, 261 bp, and 285 bp, respectively. Migration of the PCR products was slightly different in proportion to the number of CTG repeats. (B).
Fluorescence micrograph of the expressed GFP or polyL-GFP fusion protein. Nuclei were stained with Hoechst 33342. (C). Summary of the time course
of aggregation of cells transfected with pQBI25-L13, L-24 and -L32. Percent aggregation represents the number of cells with aggregates relative to
the number of GFP-positive cells at each time point. Values represent the mean of duplicate experiments.
doi:10.1371/journal.pone.0000635.g002
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shown a discrepancy between aggregate formation and cell death
[3], [24]. In contrast, in both polyQ transgenic mice and
Drosophila, interference with aggregate formation has been shown
to prolong survival and to ameliorate neuropathology [25][]–[27].
These results suggest that the process of aggregate formation is
necessary for, but does not necessarily result in, cell toxicity.
Correspondingly, the genetic gain-of-function of polyQ expansion
leads to the nucleation process of aggregate formation, but does
not have a direct toxic effect on the cells. Our results, together with
recent findings in conformational diseases, have led us to propose
an amyloid-based polyQ pathogenic pathway (Figure 6). Re-
markably, this basic pathway can explain most of the characteristic
features of polyQ diseases that are due to polyQ expansion.
Although a lower range of polyQ expansion is a normal
polymorphism, at a higher range, or threshold polyQ length,
partial conversion of a structure linked to nucleation of protein
aggregates can trigger an amyloid-precursor state, leading to the
pathogenic pathway of polyQ diseases. The neurological symp-
toms of polyQ diseases typically appear in midlife. The structural
conversion from the precursor protein to the nucleus is an
energetically unfavorable reaction, requiring a very long time
under physiological conditions [11]. This delayed disease-onset
can be considered a latent period. Compared with other
conformational diseases, the most characteristic feature of polyQ
diseases is the relationship of age-of-onset to repeat length. The
present study demonstrated that a unique structural feature of the
dependency of amyloid-precursor epitope on length of polyQ
expansions and its link to nucleation are the critical determinants
of the repeat-length related age-of-onset of HD.
In polyQ diseases, there is a selective loss of neurons, with
different cells showing different levels of vulnerability. A common
feature of amyloid-forming proteins is that a single protein can
adopt multiple distinct, self-propagating amyloid conformations,
with the spectrum of misfolded forms being determined by the
protein’s primary structure [28]–[30]. Amyloid fibril formation of
yeast prion protein Sup35 also occurs by nucleated growth
polymerization [31]. This pathway yields conformational variants
of Sup 35, resulting in strain differences in yeast prion phenotype
[31], [32]. Although this conformational variation is still un-
determined in polyQ diseases, specific amyloid conformations
adopted by each protein containing polyQ segments can affect
different cellular factors including proteins, thereby modulating
the toxic effects. Conformational diversity and selective interaction
of amyloid conformations with cellular factors may determine the
toxic effects on cells, resulting in selective loss of neurons and
phenotypic variations.
MATERIALS AND METHODS
Plasmid construction
Genomic DNA was extracted from whole blood by standard
procedures after informed consent. Truncated exon 1 of the
human HD gene, including polymorphic CAG repeats, was
amplified by PCR using the primers 59-atgaaggccttcaagtccctcaag-
39 and 59-ggcggtggcggctgttgctgctgc-39. The purified PCR frag-
ment was inserted into the Nhe1 site of the GFP expression vector,
pQBI25 (Takara, Japan), in both directions and used to transform
competent E. coli according to the manufacturer’s protocol.
Positive clones were selected by the PCR method, and all
constructs were validated by DNA sequencing (Takara customer
service). This yielded a series of fusion proteins of polyQ-GFP and
polyL-GFP encoding repeat lengths of 13, 24 and 32 (L13, L24
and L32). All constructs were transfected into COS7 cells and
observed for 120 h. We confirmed that such a lower expansion of
polyQ tracts never formed visible aggregates (data not shown).
Cell culture and transfection
COS7 cells were obtained from the Riken Cell Bank (Japan) and
maintained in Dulbecco’s modified Eagle’s medium (Nissui
Pharmaceutical, Japan) supplemented with 10% fetal bovine
serum. For transfection of plasmid DNA, cells were seeded at
1.5610
5 cells/35 mm plate, overlain with a sterile coverslip, and
grown to 70–80% confluence. The cells were washed twice with
Opti-MEM (Invitrogen) and transfected with 1.5 mg plasmid DNA
in Lipofectamine reagent (Invitrogen) for 6 h according to the
manufacturer’s instructions.
Analysis of aggregation in vivo
COS7 cells transfected with pQBI25-L13, -L24 or -L32 or vector
alone, pQBI25, were washed with phosphate-buffered saline
without Ca
2+ and Mg
2+ (PBS(-)) and fixed with 4% para-
formaldehyde for 30 min at room temperature. The cells were
washed with PBS(-), stained with 10 uM Hoechst 33342 for
15 min at room temperature, washed again with PBS(-) and
mounted with Slowfade Gold antifade reagent (Invitrogen). Cells
were serially examined by fluorescence microscopy until 120 h
Figure 3. Detection of dead cells induced by polyL-GFP fusion
proteins. (A). Fluorescence micrograph of propidium iodide (PI) stained
dead cells expressing GFP or polyL32-GFP fusion protein. (B). Summary
of the time course of cell death following transfection with pQBI25,
pQBI25-L13, -L24 and -L32. The percentage of dead cells is reported
relative to the number of GFP-positive cells at each time point
transfection. Values represent the mean of duplicate experiments.
doi:10.1371/journal.pone.0000635.g003
Amyloid-Precursor Epitope
PLoS ONE | www.plosone.org 4 July 2007 | Issue 7 | e635after transfection. The number of transfected cells with visible
aggregates and the number of transfected cells without aggregates
were counted independently in randomly chosen microscopic
fields, with approximately 300–500 transfected cells analyzed per
experiment.
Analysis of dead cells
Dead cells were detected using Live-Dead Cell Staining Kit
(Biovision), which stains dead cells with PI, a cell non-permeable
red fluorescent dye. The cells were incubated with Staining Buffer
for 15 min at 37uC, mounted with Slowfade Gold antifade
reagent, and examined by fluorescence microscopy until 96 h after
transfection. The number of transfected cells with or without PI
signal was counted in randomly chosen microscopic fields, with
approximately 300–400 transfected cells analyzed per experiment.
Western blotting analysis
In each experiment, 9.6 mg plasmid DNA were transfected into
COS7 cells on 100 mm plates; this represents an equal ratio of
plasmid DNA per square in fluorescence microscopy. Cells were
serially collected after transfection and lysed by homogenization in
50 mM Tris-HCl pH 8.0, 10% (v/v) glycerol, 5 mM EDTA,
150 mM KCl, 1 mM PMSF. Insoluble materials were removed by
centrifugation at 10,0006ga t4 uC for 10 min, and the protein
concentration of each supernatant was determined using the
Bradford procedure. To determine the time course of expression
of each construct, the amount of applied protein was adjusted in
proportion to the total amount of cellular protein in each sample,
starting with 25 mg of cellular protein at 0 h post-transfection.
Samples were electrophoresed on 7.5% SDS-polyacrylamide gels
and transblotted to nitrocellulose membranes, which were blocked
Figure 4. Expression of epitopes binding anti-GFP and anti-1C2 on soluble monomers of polyL-GFP fusion proteins. (A). Time course of anti-GFP
Ab binding of cells expressing polyL-GFP fusion proteins (M, lysate from mock transfected cells; V, lysate from cells transfected with the pQBI25
vector). (B). Western blot analysis of GFP and polyL-GFP fusion proteins successively immunoprobed with 1C2 and anti-GFP Ab. (C). Expression of anti-
GFP signal on polyL-GFP fusion proteins. The signal intensity of each band on Western blots (Figure 4A) was adjusted to be equal to that shown in
Figure 2C. Values represent mean of duplicate experiments. (D). Expression of anti-1C2 signal on the polyL-GFP fusion proteins L13, L24 and L32. The
relative signal intensities of each was determined by the results of Figure 4B, and the time course of anti-1C2 signal intensity was calculated from the
data in Figure 4C, since anti-1C2 signal intensity of 13 leucine fused to GFP was weak. (E). Integration of anti-1C2 signal intensity on polyL-GFP fusion
proteins, calculated from the results of Figure 4D using Simpson’s formula. Spearman’s correlation coefficients calculated from the data in Figure 2C
and Figure 4E were, for L13, R=0.821 (p=0.025); for L24, R=0.973 (p=0.009); and for L32, R=0.986 (p=0.014).
doi:10.1371/journal.pone.0000635.g004
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horseradish peroxidase-conjugated anti-GFP polyclonal Ab (Rock-
land) diluted 1:50,000. Equal amounts of protein lysates (50 mg)
from mock transfected cells and from cells transfected with
pQBI25-L13, -L24 or -L32, and 15 mg of protein lysate obtained
from cells 24 h after transfection with pQBI25 were analyzed on
the same blot using 1C2 (Chemicon) diluted 1:2,000. Each
membrane was incubated with horseradish peroxidase-conjugated
anti-mouse IgG (Santa Cruz) diluted 1:1000 dilution, stripped and
reprobed with anti-GFP Ab. Proteins were detected using the
enhanced chemiluminescence (ECL) detection system (Amersham
Biosciences), and signal intensity was measured by NIH Image
software.
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